MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INKT MiNK Therapeutics, Inc.

Closed Good Friday 04-17 16:00:00 EDT

7.25

-0.58

-7.41%

盘后7.25

+0.000.00%

16:47 EDT

High8.01	Low7.25	Vol2.27K
Open7.66	D1 Closing7.83	Amplitude9.71%
Mkt Cap28.76M	Tradable Cap7.31M	Total Shares3.97M
T/O17.16K	T/O Rate0.23%	Tradable Shares1.01M
P/B-1.47	ROE-1238.98%	EPS-2.86
52wk High13.79	52wk Low4.56	P/E-2.54
Dividend0.00	Div.Yield0.00	ROA-137.35%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":7.25,"timestamp":1744920000000,"preClose":7.83,"halted":0,"volume":2273,"hourTrading":{"tag":"盘后","latestPrice":7.25,"preClose":7.25,"latestTime":"16:47 EDT","volume":3,"amount":23.6,"timestamp":1744922870849},"delay":0,"floatShares":1008812,"shares":3966392,"eps":-2.858168,"marketStatus":"Closed Good Friday","change":-0.58,"latestTime":"04-17 16:00:00 EDT","open":7.655,"high":8.0099,"low":7.25,"amount":17156.384655500002,"amplitude":0.09705,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.858168,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":7.83,"preHourTrading":{"tag":"盘前","latestPrice":8,"preClose":7.8,"latestTime":"08:22 EDT","volume":20,"amount":160,"timestamp":1744892560168},"postHourTrading":{"tag":"盘后","latestPrice":7.25,"preClose":7.25,"latestTime":"16:47 EDT","volume":3,"amount":23.6,"timestamp":1744922870849},"volumeRatio":0.7032797443140938},"requestUrl":"/m/hq/s/INKT","defaultTab":"news","newsList":[{"id":"2520949172","title":"MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2520949172","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520949172?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 15:01","pubTimestamp":1742367712,"startTime":"0","endTime":"0","summary":"Cash Used in Operations: $1.7 million for Q4 2024; $9.6 million for the full year 2024.Net Loss: $10.8 million for 2024, or $2.86 per share.Net Loss Comparison: $22.5 million for 2023, or $6.54 per share.For the complete transcript of the earnings call, please refer to the full earnings call transcript.MiNK Therapeutics Inc  strengthened its leadership team by adding Dr. Robert Kadlec, a renowned leader in biodefense and pandemic preparedness, to its Board of Directors.The company expanded its innovation toolkit through a strategic collaboration with Autonomous Therapeutics, aiming to enhance its iNKT cell therapies with encrypted RNA technology.Also, what are the main focuses for 2025 regarding 797 in gastric cancer and GVHD?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mink-therapeutics-inc-inkt-q4-070152016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INKT"],"gpt_icon":0},{"id":"2520748990","title":"MiNK Therapeutics Reports 2024 Progress and Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2520748990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520748990?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 11:54","pubTimestamp":1742356470,"startTime":"0","endTime":"0","summary":"Mink Therapeutics, Inc. ( ($INKT) ) has released its Q4 earnings. Here is a breakdown of the information Mink Therapeutics, Inc. presented to its i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-reports-2024-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-reports-2024-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","PRGS","BK4139","LU2065732104.USD","INKT","LENZ"],"gpt_icon":0},{"id":"2520924019","title":"Q4 2024 Mink Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2520924019","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520924019?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 11:42","pubTimestamp":1742355749,"startTime":"0","endTime":"0","summary":"Jennifer Buell; President, Chief Executive Officer, Director; Mink Therapeutics Inc. Jack Allen; Analyst; Robert W. Baird & Co., Inc.Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded.  I'd now like to hand the call over to Zach Armen, Investor Relations. You may now begin.Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data release and partnership opportunities. These statements are subject to risk and uncertainty. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Doctor Jennifer Buell, President and Chief Executive Officer, and Christine Klaskin, Principal Finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-mink-therapeutics-inc-034229365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INKT","LENZ"],"gpt_icon":0},{"id":"2520554809","title":"Buy Rating Affirmed for MiNK Therapeutics Amid Promising Clinical Developments and Strategic Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2520554809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520554809?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 05:55","pubTimestamp":1742334910,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on INKT stock, giving a Buy rating today. Matt Phipps has given his Buy ratin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-mink-therapeutics-amid-promising-clinical-developments-and-strategic-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-mink-therapeutics-amid-promising-clinical-developments-and-strategic-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","LENZ"],"gpt_icon":0},{"id":"2520216609","title":"Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2520216609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520216609?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 22:25","pubTimestamp":1742307908,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), retaining the price target of $35.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-data-and-strategic-initiatives-drive-buy-rating-for-mink-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-data-and-strategic-initiatives-drive-buy-rating-for-mink-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","INKT"],"gpt_icon":0},{"id":"2520677186","title":"Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2520677186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520677186?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 21:32","pubTimestamp":1742304746,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMink Therapeutics Inc INKT.OQ reported a quarterly adjusted loss of 62 cents per share for the quarter ended D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL8N3Q1194:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"gpt_icon":0},{"id":"2520621288","title":"MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520621288","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520621288?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 19:37","pubTimestamp":1742297860,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.50) by 24 percent. This is a 287.5 percent decrease over losses of $(0.16) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44373715/mink-therapeutics-q4-2024-gaap-eps-0-62-misses-0-50-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","LENZ"],"gpt_icon":0},{"id":"2520297836","title":"Press Release: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2520297836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520297836?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 19:30","pubTimestamp":1742297400,"startTime":"0","endTime":"0","summary":"NEW YORK, March 18, 2025  -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T  cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET.\"Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders,\" said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. \"We made significant clinical strides, strengthened our manufacturing foundation, and forged strategic alliances. Through disciplined capital management, we are positioned to scale efficiently and seize new collaboration opportunities for value creation. With our rapid AI-driven drug discovery platform generating a world-class l","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","INKT","LENZ","BK4139","ARDS","ATS","LU2065732104.USD","BK4097","PRGS"],"gpt_icon":0},{"id":"2519801094","title":"Mink Therapeutics Inc  expected to post a loss of 50 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519801094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519801094?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 21:11","pubTimestamp":1741957865,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc  expected to post a loss of50cents a share - Earnings Preview Mink Therapeutics Inc INKT.OQ INKT.O is expected to show no change in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"gpt_icon":0},{"id":"2519876572","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2519876572","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519876572?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 18:00","pubTimestamp":1741946400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRSO","LE","LAR","RANI","ABSI","IDN","GOGO","AEVA","LXEO","GIS","LVTX","DTIL","HYPR","ERAS","AMPX","DTI","STNE","PL","HROW","CAL","HTHT","TME","OSS","FDX","GANX","INSE","ACN","FDS","JILL","LQDA","TYRA","DRI","MBRX","RLYB","SPRY","IFRX","MGNX","CNTX","LPRO","MRC","INKT","KOPN","AUTL","NRXP","CAPR","ANRO","NKTX"],"gpt_icon":1},{"id":"2516678701","title":"Mink Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2516678701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516678701?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:30","pubTimestamp":1741091401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUABPLZS6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2516567395","title":"MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2516567395","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516567395?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:30","pubTimestamp":1741091400,"startTime":"0","endTime":"0","summary":"NEW YORK, March  04, 2025  (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.(NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036371/0/en/MiNK-Therapeutics-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2024-Financial-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT","LENZ"],"gpt_icon":0},{"id":"2516618955","title":"Health Check:  Half-price sale as brokers ring the bell on Neuren shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2516618955","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516618955?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 10:19","pubTimestamp":1741054780,"startTime":"0","endTime":"0","summary":"Healthcare analysts say Neuren shares should be worth more than double what they are. Biotech sector retreats in February, despite some record results. Dimerix pockets $3.2 million payment from Japanese partner","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-1168599345-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-1168599345-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/health-check-half-price-sale-as-brokers-ring-the-bell-on-neuren-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2514067935","title":"Promising Early Results from MiNK Therapeutics’ Phase 2 Study of agenT-797 in Refractory GEC Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067935?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 19:17","pubTimestamp":1740482237,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price target of $35.00. Emily...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-early-results-from-mink-therapeutics-phase-2-study-of-agent-797-in-refractory-gec-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-early-results-from-mink-therapeutics-phase-2-study-of-agent-797-in-refractory-gec-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","INKT"],"gpt_icon":0},{"id":"2513729721","title":"MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729721","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729721?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric CancersNEW YORK, Feb.  24, 2025  (G","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3031139/0/en/MiNK-Therapeutics-Presents-First-in-Kind-Allo-iNKTs-Combination-Data-in-2L-Gastric-Cancer-at-AACR-IO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BAL","INKT","LENZ"],"gpt_icon":0},{"id":"2512441815","title":"Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2512441815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512441815?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 20:30","pubTimestamp":1740054600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nTUA36Y8CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2511583205","title":"MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2511583205","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511583205?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 02:00","pubTimestamp":1739383200,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 12, 2025  -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T  cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcomingAmerican Association for Cancer Research  IO Annual Meeting that will take place onFebruary 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company’s ongoing Phase 2 study testing AgenT-797 in combination with Agenus’ lead therapeutic combination, botensilimab and balstilimab , in patients with refractory (2L+) gastric cancer .Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 , botensilimab  with balstilimab  in PD-1 refractory gastroesophageal cancer . This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mink-therapeutics-present-updated-data-180000749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IO","LENZ","INKT","BK4563","BK4179"],"gpt_icon":0},{"id":"2506953770","title":"Mink Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2506953770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506953770?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 08:55","pubTimestamp":1738025705,"startTime":"0","endTime":"0","summary":"19:50 EST Mink Therapeutics (INKT) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-inc-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-inc-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT","LENZ"],"gpt_icon":0},{"id":"2505408650","title":"MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI","url":"https://stock-news.laohu8.com/highlight/detail?id=2505408650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505408650?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 03:13","pubTimestamp":1737659580,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  23, 2025  (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/23/3014550/0/en/MiNK-Therapeutics-Targets-Immune-Reconstitution-to-Combat-Advanced-Gastroesophageal-Cancers-with-Novel-Combination-of-Allo-iNKTs-plus-BOT-BAL-at-ASCO-GI.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","IE00B19Z4B17.USD","INKT","AEIS","BAL","BK4139","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IE0031619046.USD","BK4157"],"gpt_icon":0},{"id":"2505665780","title":"Mink Therapeutics Inc - to Effect 1-for-10 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2505665780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505665780?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 05:54","pubTimestamp":1737496453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH1XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0435},{"period":"1month","weight":-0.1201},{"period":"3month","weight":-0.1761},{"period":"6month","weight":0.0615},{"period":"1year","weight":-0.2079},{"period":"ytd","weight":0.0403}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.065869},{"month":2,"riseRate":0.25,"avgChangeRate":-0.041821},{"month":3,"riseRate":0,"avgChangeRate":-0.089419},{"month":4,"riseRate":0.25,"avgChangeRate":-0.032696},{"month":5,"riseRate":0,"avgChangeRate":-0.114999},{"month":6,"riseRate":0.333333,"avgChangeRate":0.027139},{"month":7,"riseRate":0,"avgChangeRate":-0.063379},{"month":8,"riseRate":0.333333,"avgChangeRate":0.214912},{"month":9,"riseRate":0,"avgChangeRate":-0.171057},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.029184},{"month":11,"riseRate":0.75,"avgChangeRate":-0.020151},{"month":12,"riseRate":0.25,"avgChangeRate":-0.165057}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction